Sonic Labs Clarification: AC Does Not Unilaterally Control the Development Fund, No Misappropriation of Funds by the Foundation
BlockBeats News, February 13th, Sonic Labs issued a statement regarding recent public comments about Andre Cronje and the Sonic network. In 2018, a Korean team launched an ICO for Fantom (now rebranded as Sonic) but failed to deliver a functional product due to mismanagement, leading to a significant loss of funds. In June 2018, Andre Cronje joined and relaunched Fantom. When Andre Cronje joined, the treasury held non-FTM assets of less than $5 million, which grew to a nine-figure sum between 2020 and 2021.
Sonic Labs further stated that Andre did not design the original Fantom tokenomics, as it was created by the original Korean team in 2018 and later modified through on-chain governance. Andre also does not unilaterally safeguard or control the Sonic Development Fund. Andre has never abandoned Fantom/Sonic, designed the original technology, expanded funding, and continues to serve as a technical advisor, regularly guiding the technical team. There has been no misappropriation of funds.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
